Stock Evaluator: Atara Biotherapeutics, Inc. (ATRA)

Atara Biotherapeutics, Inc. ATRA

$6.33 -0.01 -0.16%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 36,417
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Commentary & Analysis


Financial Summary

Share Statistics ATRA Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $64.5 $203.5 20%
Shares Out (Mil) 15.3 55.2 26%
Institutional Ownership 84.9% 93.3% 52%
Float (Mil) 4.8 40.4 12%
Beta 0.32 1.05 18%
Avg Daily Volume (000s) 27 569 23%
Price Change
(52-week)
(53.9%) 38.8% 20%
Growth ATRA Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) 16.1% (10.7%) 66%
EPS (5yr) 15.2% 15.4% 57
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (15.2%) (15.7%) 50%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($0.090) ($0.770) $1.600
Month Ago EPS ($0.190) ($0.950) $1.545
# Rev Up 0 1 1
# Rev Down 0 0 0
Three Months Ago EPS ($0.320) ($1.270) $1.565
Year/Year Chg (40.0%) (130.0%) (76.3%)
Financials ATRA Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $4 $40 5%
Net Income (TTM) (Mil) ($15) ($44) 26%
EPS (TTM) ($1.007) ($1.400) 21%
Operating Cash Flow (TTM) (Mil) ($13) ($35) 18%
Net Cash Flow (TTM) (Mil) na $-0 na
Long-Term Debt (Q1) (Mil) $9 $4 27%
Enterprise Value (Q1) (Mil) $65 $142 19%
Valuation ATRA Industry
Median
Percentile
(All Stocks)
P/B na 1.96 na
P/E na 16.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios ATRA Industry
Median
Percentile
(All Stocks)
Gross Margin 103.3% 67.6% 100%
Net Margin (368.6%) (50.8%) 3%
ROA (59.9%) (47.0%) 9%
ROE 39.2% (51.8%) 91%
Liabilities to Assets 303.7% 29.6% 100%
F-Score 3 3 18%

Atara Biotherapeutics, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors